Nandrolone decanoate relieves joint pain in hypogonadal men : a novel prospective pilot study and review of the literature / Alexander J. Tatem, Levi C. Holland, Jason Kovac, Jonathan A. Beilan, Larry I. Lipshultz. - (Translational Andrology and Urology 9 (2020) Supplement 2 (March); p. S186-S194)
- PMID: 32257859
- PMCID: PMC7108994
- DOI: 10.21037/tau.2019.11.03
Abstract
Testosterone is an archetypal androgenic-anabolic steroid (AAS), while its exogenous administration is considered to be the gold standard for the treatment of male hypogonadism. The benefits are not due to its intrinsic nature alone but are due to the result of its interactions with the androgen receptor (AR). As the management of hypogonadism continues to advance into the modern era, it would be preferable for modern andrologists to have multiple tools at their disposal to influence AR activity. Nandrolone, or 19-nortestosterone, is one such compound. In the following review of the literature, we examine the history, pharmacology, and clinical applications of this medication. We also present the results of our novel pilot study examining the favorable effects of nandrolone on joint pain for hypogonadal men.
Keywords: Nandrolone; andrology; arthritis; hypogonadism; joint pain; testosterone; testosterone
